A study found no significant HRQOL differences between Erleada-based therapies and ADT plus AAP for advanced castration-sensitive prostate cancer.

PYLARIFY ® (piflufolastat F 18) Injection is a radioactive diagnostic agent indicated or positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with ...

Israeli pharmaceutical company RedHill Biopharma has initiated a placebo-controlled Phase II trial to assess the combination ...